share_log
Moomoo 24/7 ·  Jan 29 08:41
Lixte Biotechnology Announces Dosing Of First Patient In Phase 1b.2 Trial Assessing LIXTE's LB-100 And GSK's Immunotherapy Dostarlimab-gxly In Ovarian Clear Cell Carcinoma Trial
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment